RxDoctor Payments Data

Jillian Pattison, DO

Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1528420783

Payments from drug & device makers

$625in general payments, 2019–2025

Across 17 payments — averaging $36.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sequel Med Tech, LLC$163
  • BETA Bionics, Inc.$110
  • Insulet Corporation$104
  • Lilly USA, LLC$69
  • Medtronic$32
  • Ascendis Pharma Endocrinology Inc$26
  • plus $121 from 7 others

What the payments were for

  • Food & beverage$60897%
  • Education$173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$625 in reported general payments places this provider in the 35th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$29,641
Medicare patients
134
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$76,633
JardianceEmpagliflozin43$44,435
TrulicityDulaglutide22$34,662
MounjaroTirzepatide12$19,092
TradjentaLinagliptin11$16,669
JanuviaSitagliptin Phosphate20$15,319
FarxigaDapagliflozin Propanediol12$11,741
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$9,933
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$5,712
Cinacalcet Hcl16$4,760
Novolog FlexpenInsulin Aspart12$3,713
Nano 2nd Gen Pen NeedlePen Needle, Diabetic18$2,545
Levothyroxine Sodium160$1,822
SynthroidLevothyroxine Sodium14$1,417
Hydrocortisone21$1,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$76,63360 claims
Lilly USA, LLCTrulicity, Mounjaro$69$53,75434 claims
AstraZenecaFarxiga$15$11,74112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →